TLIS — Talis Biomedical Balance Sheet
0.000.00%
- $2.92m
- -$56.95m
- $2.13m
- 47
- 39
- 26
- 30
Annual balance sheet for Talis Biomedical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 21.6 | 138 | 233 | 130 | 76.7 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1.81 | 0.471 | 0.183 | 0.308 | 0.05 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 24.1 | 189 | 236 | 133 | 77.7 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1.53 | 9.68 | 23.4 | 34.2 | 15.4 |
Other Long Term Assets | |||||
Total Assets | 25.7 | 198 | 266 | 169 | 94.7 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 4.04 | 16 | 19.1 | 12.7 | 8.77 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 4.12 | 16 | 31.9 | 42.6 | 25.6 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 21.6 | 182 | 234 | 127 | 69.1 |
Total Liabilities & Shareholders' Equity | 25.7 | 198 | 266 | 169 | 94.7 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |